Multiple Myeloma Hub
Multiple Myeloma Hub
Logo for the European Board for Accreditation of Continuing Education for Health Professionals

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Scientific Education Support (SES). ACHL is accredited by the ACCME to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

8:00 (EST)
Sagar Lonial

Welcome and introductions

08:15 (EST)
Naresh Bumma

BCMA-directed bispecific antibodies

8:35 (EST)
Amrita Krishnan

Beyond BCMA: Novel strategies using bispecific antibodies

8:55 (EST)
Sergio Giralt

Practical management of adverse events associated with immunotherapies

9:15 (EST)
Sagar Lonial

Looking to the future

9:25 (EST)
Sagar Lonial

Closing remarks

Guidelines require that learners in CME activities be made aware of all relevant financial relationships affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose financial relationships held within 24 months and that relevant financial relationships are mitigated before a CME activity occurs. Complete information will be provided to learners prior to the start of the educational activity.

Learning objectives

Upon completion of this activity, participants should be able to:

  • Describe novel therapeutic targets in MM and explain the mechanisms of action for new agents in MM
  • State the rationale for selecting treatments in relapsed/refractory disease based on disease- and patient-related factors
  • Recall key safety and efficacy data for new agents and relate this to treatment selection
  • Employ patient-specific considerations in the development of personalized treatment plans

Registration form

Registration is free. Please complete the form and submit to register.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy